Business Context and Reporting Period
This Form 6-K filing by Genmab A/S covers the month of February 2026, with the report dated February 24, 2026. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The primary purpose of this report is to disclose a capital increase resulting from the exercise of employee warrants.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate action regarding capital structure rather than operational financial performance.
Material Changes
- Capital Increase: The company announced a capital increase resulting from the exercise of employee warrants.
- Exhibit 99.1: The filing includes a company announcement dated February 24, 2026, detailing the specifics of the warrant exercise.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items beyond the disclosure of the warrant exercise. The report is incorporated by reference into the company's registration statements on Form S-8.
Investor Verification Checklist
- Verify the exact number of shares issued and the total capital raised from the employee warrant exercise detailed in Exhibit 99.1.
- Confirm the impact of this capital increase on the company's total outstanding share count and potential dilution.
- Review the specific terms of the warrants exercised to understand the pricing and conditions.